Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...
Stargaze Holds Annual Meeting of Shareholders
Change the total number of shares which Stargaze is authorized to issue to 1,000,000,000, consisting of 990,000,000 shares of common stock and 10,000,000 shares of preferred stock, with 2,500,000 ...